The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.
Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with increased risk of incident diabetic retinopathy, according to a study published in Diabetes Care.
GLP-1 receptor agonists (RAs) lower blood sugar levels by promoting insulin secretion. Patients who use these drugs to treat type 2 diabetes not only see improved glycemic control but may also lose weight. In fact, one GLP-1 therapy, liraglutide, is approved in a formulation to treat obesity. Studies have also been published showing cardiovascular benefits for liraglutide and semaglutide, and FDA granted a cardiovascular indication for liraglutide last year.
Read About Once-Weekly Semaglutide
The SUSTAIN-6 study had pointed to a possible worsening of retinopathy with semaglutide, although this was not borne out in the SUSTAIN-7 trial prior to approval. The claims study published this week evaluated data from 77,115 patients in the United Kingdom who had type 2 diabetes (T2D) and began taking therapies between January 2007 and September 2015. Researchers compared those taking GLP-1 RAs with those taking 2 or more oral antidiabetic drugs and, in a separate analysis, compared those taking GLP-1 RAs with those taking insulin.
During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with those taking 2 or more oral drugs, the risk of retinopathy among those taking the GLP-1 class was the same (hazard ratio [HR], 1.00; 95% CI, 0.85-1.17). Those taking the GLP-1 class had a 33% reduced risk of retinopathy compared with those taking insulin (HR, 0.67; 95% CI, 0.51-0.90). The authors wrote that the apparent lower risk of diabetic retinopathy may be due to residual confounding.
Reference
Douros A, Filion KB, Yin H, et al. Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy [published online August 27, 2018]. Diabetes Care. 2018. doi: 10.2337/dc17-2280.
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More